NCT03100825CompletedPhase 3
A Multicenter, Open-label, Single Arm, 52-week Treatment Study to Assess the Safety of QVM149 in Japanese Patients With Asthma
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 3
- Status
- Completed
- Sponsor
- Novartis Pharmaceuticals
- Enrollment
- 96
- Locations
- 1
- Primary Endpoint
- Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs)
Study Overview
Brief Summary
The purpose of this study is to provide long term safety data of QVM149 in Japanese patients with asthma for the registration of QVM149 in Japan.
Study Design
- Study Type
- Interventional
- Allocation
- Non Randomized
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Written informed consent must be obtained before any assessment is performed.
- •Male and female adult patient ≥ 18 years old.
- •Patients with a diagnosis of persistent asthma (GINA 2016) for a period of at least 1 year prior to Visit
- •Patients who have used medium or high dose of ICS/LABA combinations for asthma for at least 3 months and at stable dose and regimen for at least 4 weeks prior to Visit
- •An ACQ-7 score ≥ 1.5 at Visits
- •Pre-bronchodilator FEV1 of ≥ 40% and ≤ 85% of the predicted normal value for the patient after withholding bronchodilators at Visit
- •o Repeating is allowed once only. Repeating of percentage predicted FEV1 should be done in an ad-hoc visit to be scheduled on a date that would provide sufficient time to receive confirmation from the spirometry data central reviewer of the validity of the assessment before Visit
- •Patients must demonstrate reversibility defined as an increase in FEV1 of ≥ 12% and 200 mL within 15 to 30 minutes after administration of 400 µg of salbutamol at Visit
- •Spacer devices are permitted during reversibility testing only. The Investigator or delegate may decide whether or not to use a spacer for the reversibility testing.
- •If reversibility is not proven at Visit 2, patients may be permitted to enter the study with historical evidence of reversibility that was performed within 5 years prior to Visit
- •Alternatively, patients may be permitted to enter the study with a historical positive bronchoprovocation test (defined as a provoked fall in FEV1 of 20% by bronchoconstriction agent e.g., methacholine, histamine) or equivalent test (e.g., astography) that was performed within 5 years prior to Visit
- •If reversibility is not proven at Visit 2 and historical data is not available, reversibility should be repeated once in an ad-hoc visit scheduled as close as possible from the first attempt (but not on the same day).
Exclusion Criteria
- •Patients who have had an asthma attack/exacerbation requiring systemic steroids or hospitalization or emergency room visit within 6-weeks of Visit
- •Patients who have ever required intubation for a severe asthma attack/exacerbation.
- •Patients who have a clinical condition which is likely to be worsened by ICS administration (e.g. glaucoma, cataract and fragility fractures) who are according to investigator's medical judgment at risk participating in the study.
- •Patients with narrow-angle glaucoma, symptomatic benign prostatic hyperplasia (BPH) or bladder-neck obstruction or severe renal impairment or urinary retention. BPH patients who are stable on treatment can be considered.
- •Patients who have had a respiratory tract infection or asthma worsening as determined by investigator within 4 weeks prior to Visit 1 or between Visit 1 and Visit
- •Patients may be re-screened 4 weeks after recovery from their respiratory tract infection or asthma worsening.
- •Patients with a history of chronic lung diseases other than asthma, including (but not limited to) COPD, sarcoidosis, interstitial lung disease, cystic fibrosis, clinically significant bronchiectasis and active tuberculosis.
- •Patients with severe narcolepsy and/or insomnia
- •Pregnant or nursing (lactating) women
- •Women of child-bearing potential unless they are using highly effective methods of contraception during dosing and for 30 days after stopping of investigational medication
Arms & Interventions
QVM149
Experimental
All eligible patients take QVM149 150/50/160 μg once daily over 52 weeks.
Intervention: QVM149 (Drug)
Outcomes
Primary Outcomes
Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs)
Time Frame: Up to 52 Weeks
An adverse event (AE) was any untoward medical occurrence (example; any unfavorable and unintended sign including abnormal laboratory findings, symptom or disease) in a participant or clinical investigation participant after providing written informed consent for participation in the study until the end of study visit. TEAEs were defined as adverse events started on or after the time of the first inhalation of study drug but no later than 7 days after the last administration (30 days in the case of SAEs). SAE was defined as any adverse event (appearance of \[or worsening of any pre-existing\]) undesirable sign, symptom or medical conditions which is fatal or life-threatening or results in persistent or significant disability/incapacity or constitutes a congenital anomaly/birth defect or requires inpatient hospitalization or prolongation of existing hospitalization or is medically significant.
Secondary Outcomes
- Change From Baseline (Pre-dose) Forced Expiratory Volume in One Second (FEV1) at Week 26 and 52(Baseline (Pre-dose), Week 26, Week 52)
- Change From Baseline (Pre-dose) Forced Vital Capacity (FVC) at Week 26 and 52(Baseline (Pre-dose), Week 26, Week 52)
- Change From Baseline in Daily Number of Puffs of Rescue Medication Over 52 Weeks(Baseline up to week 52)
- Change From Baseline in Morning and Evening Peak Expiratory Flow (PEF) Over 52 Weeks(Baseline up to week 52)
- Change From Baseline in Asthma Control Questionnaire-7 (ACQ-7) Total Score at Week 26 and 52(Baseline, Week 26, Week 52)
- Proportion of Participants Who Achieved Clinically Meaningful Improvement Threshold in ACQ-7 Score (Decrease of Greater Than or Equal to 0.5 Units in ACQ-7) at Week 26 and 52(Week 26, Week 52)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 3
A Long-term Safety Study of QMF149 in Japanese Participants With AsthmaAsthmaNCT03100500Novartis Pharmaceuticals51
Completed
Phase 3
A Study to Assess the Long-term Safety of QVA149Chronic Obstructive Pulmonary DiseaseNCT01120717Novartis Pharmaceuticals339
Completed
Phase 3
A Study to Assess the Efficacy, Safety and Tolerability of Once-daily (q.d.) QVA149 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)Chronic Obstructive Pulmonary Disease (COPD)NCT01202188Novartis Pharmaceuticals2,144
Completed
Phase 3
QVA vs. Salmeterol/Fluticasone, 52-week Exacerbation Study, FLAME (EFfect of Indacaterol Glycopyronium Vs Fluticasone Salmeterol on COPD Exacerbations)Chronic Obstructive Pulmonary Disease (COPD)NCT01782326Novartis Pharmaceuticals3,362
Completed
Phase 3
A 12 Week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation.Chronic Obstructive Pulmonary Disease (COPD)NCT01727141Novartis Pharmaceuticals1,042